Domestic companies will have delay on launching blockbuster ‘Trajenta’ generics
Domestic generic companies failed in challenging the substance patent of antidiabetic ‘Trajenta.’
In the past, domestic companies won nullification suits for its crystalline and formulation patents which are expiring the latest.
Its crystalline and formulation patents are expected to be expired...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
